Analyst consensus rating
C4 Therapeutics, Inc. Analyst Consensus Rating
CCCC analyst consensus rating, coverage count and price target evidence.
Direct answer
C4 Therapeutics, Inc.'s consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.33.
Forecast evidence checked August 14, 2026.
Get free C4 Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.08
- Average price target
- $13.33
- High price target
- $30.00
- Low price target
- $7.00
- Target upside
- +226.8%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- August 14, 2026
- Valid through
- August 21, 2026